Therapeutics in Dermatology
A reference textbook in dermatology
 You are visiting a Fondation René Touraine website.    Donate English Français

  Health professionals

Home > English > Book > Drugs >


26 March 2015, by SORIA A.


Omalizumab (Xolair®) is a recombinant humanized IgG1 kappa monoclonal anti-IgE antibody. It has been marketed since 2003 as additional treatment for severe persistent allergic asthma in adults, adolescents and children (aged 6 up to 11 years).

Its mechanism of action has not been clearly elucidated in chronic urticaria. It binds to free IgE inhibiting the interaction of IgE with the high-affinity IgE receptor (FcεRI). This inhibition leads to a rapid decrease in the serum of free IgE levels after administration of omalizumab. Furthermore, omalizumab reduces the number of FcεRI receptors on basophils.

× N.B. : This limited content is for the general public. If you are a health professional, click here to register for free and gain access to a dedicated deeper content.
If you already have an account, log in!

Follow us


René Touraine Foundation